Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination

References

• Thomas M, Halpin DMG, Miravitlles M. When is dual bronchodilation indicated in COPD? COPD. 2017;12:2291–2305. doi:10.2147/COPD.S138554.
   Google Scholar
• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 Report; 2020. [Last accessed 2020 Mar 7]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.
   Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. doi:10.1124/pr.119.018150.
   PubMed Web of Science ®Google Scholar
• Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229. doi:10.1001/jamainternmed.2017.7720.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):1602245. doi:10.1183/13993003.02245-2016.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Cazzola M, Calzetta L. Cardiovascular disease in chronic respiratory disorders and beyond. J Am Coll Cardiol. 2019;73(17):2178–2180. doi:10.1016/j.jacc.2018.11.068.
   PubMed Web of Science ®Google Scholar
• Carter P, Lagan J, Fortune C, et al. Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. 2019;73(17):2166–2177. doi:10.1016/j.jacc.2018.11.063.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ora J, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. COPD. 2017;12:3469–3485. doi:10.2147/COPD.S146338.
   Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016;39(6):501–508. doi:10.1007/s40264-016-0402-4.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.646.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101841. doi:10.1016/j.pupt.2019.101841.
   PubMed Web of Science ®Google Scholar
• Gershon AS, Jafarzadeh SR, Wilson KC, et al. Clinical knowledge from observational studies. everything you wanted to know but were afraid to ask. Am J Respir Crit Care Med. 2018;198(7):859–867. doi:10.1164/rccm.201801-0118PP.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1.
   PubMed Web of Science ®Google Scholar
• Deeks J, Higgins J, Altman D. Chapter 9–Analysing data and undertaking meta-analyses: Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. In: Cochrane handbook for systematic reviews of interventions version. Vol. 5; 2011.
   Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019;20(6):737–750. doi:10.1080/14656566.2019.1570133.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Matera MG, et al. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018;17(6):589–596. doi:10.1080/14740338.2018.1472232.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Available from: https://handbook-5-1.cochrane.org/chapter_9/9_6_4_meta_regression.htm. The Cochrane Collaboration. 2011;9.6.4 Meta-regression.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4.
   PubMedGoogle Scholar
• Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Soft. 2012;49(5):1–15. doi:10.18637/jss.v049.i05.
   Web of Science ®Google Scholar
• Calzetta L, Crupi R, Roncada P, et al. Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference. Equine Vet J. 2020;52(2):305–313. doi:10.1111/evj.13137.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Roncada P, di Cave D, et al. Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. Equine Vet J. 2017;49(6):710–717. doi:10.1111/evj.12680.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. doi:10.1016/j.jclinepi.2010.04.026.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–461. doi:10.1183/16000617.00002215.
   PubMed Web of Science ®Google Scholar
• DeCoster J. Meta-analysis notes; 2004. [accessed 2017 June 14. Available from: http://www.stat-help.com/meta.pdf.
   Google Scholar
• Turner JR, Durham TA. Meta-methodology: conducting and reporting meta-analyses. J Clin Hypertens. 2014;16(2):91–93. doi:10.1111/jch.12215.
   PubMed Web of Science ®Google Scholar
• Shen Y, Cai W, Lei S, et al. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD. 2013;11(3):131230073230003–131230073230008. doi:10.3109/15412555.2013.858315.
   Google Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017.
   Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017;14(5):552–563. doi:10.1080/15412555.2017.1347918.
   PubMedGoogle Scholar
• European Commission. A guideline on summary of product characteristics (SmPC); 2009. [accessed 2017 June 22]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf
   Google Scholar
• Sullivan KM, Dean A, Soe MM. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep. 2009;124(3):471–474. doi:10.1177/003335490912400320.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344.
   PubMed Web of Science ®Google Scholar
• Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. doi:10.1164/rccm.201706-1288OC.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348. doi:10.1183/13993003.01348-2016.
   PubMed Web of Science ®Google Scholar
• Ichinose M, Kato M, Takizawa A, et al. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017;55(2):121–129. doi:10.1016/j.resinv.2016.09.004.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59. doi:10.1016/j.pupt.2015.04.002.
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.00136014.
   PubMed Web of Science ®Google Scholar
• Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. doi:10.1016/j.jclinepi.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Kardos P, Worsley S, Singh D, et al. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. COPD. 2016;11:2885–2895. doi:10.2147/COPD.S118867.
   Google Scholar
• Pahus L, Burgel PR, Roche N, et al. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019;19(1):127. doi:10.1186/s12890-019-0882-y.
   PubMedGoogle Scholar
• Suissa S, Dell'Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. Chest. 2017;151(1):60–67. doi:10.1016/j.chest.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, Ghersi D. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj. 2015;349(1):g7647–g7647. doi:10.1136/bmj.g7647.
   Web of Science ®Google Scholar
• Scichilone N, Basile M, Battaglia S, et al. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?. Respiration. 2014;87(1):11–17. doi:10.1159/000355082.
   PubMed Web of Science ®Google Scholar
• Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–1320. doi:10.1016/j.rmed.2006.10.011.
   PubMed Web of Science ®Google Scholar
• Faraoni D, Schaefer ST. Randomized controlled trials vs. observational studies: why not just live together? BMC Anesthesiol. 2016;16(1):102. doi:10.1186/s12871-016-0265-3.
   PubMedGoogle Scholar
• Sylvester RJ, Canfield SE, Lam TBL, et al. Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree. European Urology. 2017;71(5):811–819. doi:10.1016/j.eururo.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses. Pulm Ther. 2019;5(2):110–117. doi:10.1007/s41030-019-00102-8.
   Google Scholar